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Is there a future for small molecule drugs in the treatment of
rheumatic diseases?
Joanna Stanczyk, Caroline Ospelt and Steffen Gay
Introduction
The remarkable advance and benefit of biologics, fore-
most antitumour necrosis factor (TNF) therapeutics, in
the control of disease activity and joint destruction in
patients with rheumatic disorders is indisputable. It is,
however, also apparent that these drugs fail to achieve an
American College of Rheumatology (ACR) 70 response
in about 40% of the patients with rheumatoid arthritis
(RA). Moreover, primary or secondary resistance to bio-
logical therapy represents a substantial complication in a
significant group of patients. Thus, there is still an unmet
therapeutic need in the management of inflammatory
autoimmune diseases and drug development research is
actively seeking new solutions [1,2].
Small molecules are low molecular weight (<1 kDa)
compounds that have a potent biological effect. Small
molecules typically bind to cellular structures such as
surface receptors, intracellular signalling proteins and
enzymes with subsequent modulation of their function.
Most of the commonly used drugs, including disease
modifying antirheumatic drugs (DMARDs), are small
molecules. For drug development, small molecules pro-
vide a significant advantage due to the fact that a wide
range of these compounds can be synthesized in a rela-
tively short period of time and can be easily screened for
specificity and capacity of binding with a target. In
addition, in contrast to biologicals, small molecules are
orally bioavailable and their manufacturing is cost-effec-
tive, which is an important advantage for patients and
healthcare systems. For these reasons, there is a constant
substantial interest in novel small molecules for the
treatment of rheumatic disorders, and more than half
of the new anti-inflammatory therapeutics currently
tested in preclinical and clinical phases are small mol-
ecules. The idea behind this effort is the development of
an oral cytokine inhibitor being equally or more effective
than biological drugs but having all the advantages of
small molecules.
In the current review, we aim to update on the recent
advances in the field of small molecule research for the
treatment of rheumatic conditions and to assess the
prospects of novel small molecules to enter clinical use
(Table 1). We also emphasize that novel approaches are
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Purpose of review
In this review, we outline the landscape of recent developments regarding small
molecule compounds for the treatment of inflammatory disorders by discussing drug
candidates currently in the pipeline. We also stress the fact that novel techniques are
available to evaluate the safety of new therapeutics at an early stage of development.
Recent findings
Regulation of signal transduction has evolved into an important field of drug research,
and small molecule inhibitors of a number of pathways are tested as new anti-
inflammatory agents. For rheumatic diseases, specific Jak3 and Syk inhibitors are, so far,
the most successful compounds due to their good efficacy, representing a significant
advantage over p38mitogen-activated protein kinase inhibitors. Additional benefit in the
treatment of inflammatory diseases may be provided by targeting CD80, IL-12/IL-23,
AP-1 transcription factor and receptors modulating cellular activation like chemokine
receptors, Toll-like receptors and adenosine A3 receptor.
Summary
There is a big hope that novel small molecule drugs, which are rationally designed,
based on scientific advancements and biotechnological improvements, will achieve or
even exceed efficacy of protein drugs. Thereby, new therapeutic alternatives would be
given, and chances for improved outcomes in the care of rheumatic patients provided.
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needed to evaluate the tolerability of new drugs at an
early stage of development.
Inhibition of tyrosine kinases
Most important for the effectiveness of small molecule
therapeutics are the identification and targeting of mol-
ecular pathways and molecules that play a key role in the
development of the disease. Thus, comprehension of
intracellular signalling pathways, which govern initiation
and maintenance of inflammation, is a prerequisite for
rational design of novel pharmacologicals aiming at com-
bating excessive immune activation. The last decade of
ongoing intensive research in this field provided deep
insights into the molecular basis of inflammatory dis-
orders [3], paving the way for the development of signal
transduction therapy into one of the most important areas
of drug research [4].
There are some examples of successful application of
therapeutics targeting signal transduction in clinical medi-
cine. Imatinib mesylate- a potent inhibitor of tyrosine
kinases, including platelet-derived growth factor (PDGF)
receptor, c-Kit and c-Abl related kinases- is an established
treatment for chronic myeloid leukaemia and gastrointes-
tinal stromal tumours. As c-Abl has been recently ident-
ified as an important molecule in the transforming growth
factor (TGF)-b signalling [5], it was suggested that
imatinib through dual inhibition of PDGF and TGF-b
might inhibit fibrosis- a condition that cannot be success-
fully approached by any known treatment so far. As
demonstrated by Distler et al. [6] imatinib mesylate
has a potent dose-dependent antifibrotic effect in vitro
in dermal fibroblasts and in vivo in bleomycin-induced
experimental dermal fibrosis, without evidence of toxic
side effects. The first results of currently ongoing clinical
trials evaluating efficacy and safety of imatinibmesylate in
patients with severe cutaneous scleroderma or systemic
sclerosis (SSc) with severe cutaneous involvement are
awaited. In addition to imatinib, the novel tyrosine kinase
inhibitors, nilotinib and dasatinib, have emerged as highly
promising therapeutic agents against fibrosis in patients
with SSc [7]. Interestingly, imatinib mesylate and other
small molecule tyrosine kinase inhibitors proved to be
beneficial in refractory cases of other inflammatory dis-
eases, particularly characterized by increased proliferation
of fibroblasts, like RA [8].
The nonreceptor tyrosine kinase Janus kinase 3 (Jak3)
and signal transducer and activator of transcription (Stat)
are crucial for transmitting signals from a common g chain
of a number of receptors for cytokines, including INF-g,
IL-6, IL-2, IL-4, IL-7, IL-12 and IL-15. All of these have
been shown to be implicated in the pathogenesis of RA.
Therefore, intervening with the activation of this path-
way might represent an alternative approach to suppress
synovial inflammation and disease activity [9]. Interest-
ingly, expression of Jak3, Stat1, Stat4 and Stat6 in RA
synovium decreases in response to standard treatment
with conventional DMARDs [10]. Moreover, as expres-
sion of Jak3 is restricted to immune cells, the risk for
off-target side effects appears reduced, which might be
an advantage over inhibitors of p38 mitogen-activated
protein kinase (MAPK).
Recently, selective inhibitors of Jak were suggested as
potential novel anti-inflammatory treatment for RA and
psoriasis. For the treatment of arthritis, CP-690 550- a
selective inhibitor of Jak3 (Pfizer; New York City, New
York, USA)- is a leading compound in clinical phases of
development. Initially designed as an immunosuppressive
agent for application in organ transplants, CP-690 550
turned out to have a potent anti-inflammatory effect
and, at the same time, a relatively favourable safety
profile [11]. A dose ranging phase II clinical trial [12] in
264 patients, who were resistant to methotrexate (MTX)
and biologics, showed the best reported results so far for a
small molecule tested in RA. CP-690 550 applied over
6 weeks in three increasing dosages proved to be superior
to placebo in all study arms. The ACR response criteria
were met in 70–81% for ACR20, 33–54% for ACR50 and
in 13–28% for ACR70. Respective values for a placebo
group were the following: ACR20 29%, ACR50 6% and
ACR70 3%. Currently, another 6-month long phase II
study assessing efficacy and safety of CP-690 550 in
patients with RA is ongoing.
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Table 1 Small molecule compounds under clinical development for rheumatic conditions
Target Target function Drug candidates Disease Status
Jak Cytokine signalling CP-690 550, INCB18424 RA, psoriasis, CD Phase II, I
Syk Immunoreceptor signalling,
cytokine production
Tamatinib fosdium RA, allergic asthma Phase II
p38 MAPK Cytokine production, matrix degradation VX-702, ARRY-797 RA, psoriasis, CD Phase II, I
PDGFR, c-kit, ABL
kinases
Fibrosis, pannus formation,
cytokine production
Imatinib mesylate SSc, PAH, RA,
spondyloarthropaties
Phase II
IL-12/23 Th1-dependent immune response Apilimod mesylate CD, RA Phase II
CD80 T cell activation RhuDex RA Phase II
CCR5 Cell recruitment Maraviroc RA, HIV infection Phase II
CD, Crohn’s disease; MAPK, mitogen-activated protein kinase; PAH, pulmonary arterial hypertension; RA, rheumatoid arthritis; SSc, systemic
sclerosis.
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Another Jak inhibitor under preclinical development is
INCB18424 (Incyte Corporation; Wilmington, Delaware,
USA). Its efficacy has been demonstrated in rodent
models of arthritis, and a phase I trial in healthy volun-
teers is under way [13].
Spleen tyrosine kinase (Syk), belonging to intracellular
tyrosine kinases, is a key molecule in the signalling from
immunoreceptors such as Fc receptor and B-cell receptor
[14]. Moreover, Syk has been shown to be constitutively
expressed in RA synovial fibroblasts, and its activation by
IL-1b and TNF-a in turn initiates MAPK cascade [15].
In a recently completed phase II clinical trial involving
189 patients with RA, the oral Syk inhibitor R788
(tamatinib fosdium; Rigel Pharmaceuticals, San
Francisco, California, USA) showed statistically signi-
ficant improvements in ACR20, ACR50, ACR70 and
DAS28 and a good tolerability was demonstrated.
Inhibition of p38 mitogen-activated protein
kinase pathway
The p38MAPK signalling cascade has a prominent role in
the development of inflammation by mediating cellular
response to stress, pathogens and cytokines. Hyperactiva-
tion of p38MAPK, along with resultant overproduction of
IL-1b andTNF-a, is a hallmark of inflammatorydisorders,
such as RA, spondylarthropathies, inflammatory bowel
disease and psoriasis [16]. As components of the p38
MAPK pathway converge various stimulatory signals
and mediate expression of numerous genes, from a mol-
ecular perspective, they appear as promising targets for
anti-inflammatory interventions [17]. It is, however,
important to note that not more than one-third of TNF-
a-induced genes in synovial fibroblasts of patientswithRA
are p38 MAPK dependent [18]. In addition, as a major
induction of TNF-a in vivo is mediated by Toll-like
receptors (TLRs) [19], which only in part signal through
p38MAPK, TNF-a appears to be above the major induc-
tion of p38. These observations point to the notion that
inhibition of p38 might not achieve the excellent results
observed for the blockade of TNF-a.
Early p38 MAPK inhibitors showed only limited success,
primarily due to their undesired pharmacological inhi-
bition of physiologically important kinases and conse-
quent dose-dependent toxicities (liver and central ner-
vous system toxicity, impaired host defence) [20].
Therefore, selective inhibition of p38 in activated
immune cells and preservation of the regulatory role of
p38 kinases have been the major challenges for novel p38
inhibitors. Currently, new generations of p38 MAPK
inhibitors, optimised in terms of specificity and potency,
are entering preclinical and clinical trials. One of the
leading compounds is VX-702 (Vertex Pharmaceuticals,
Cambridge, Massachusetts, USA). A phase II clinical trial
of VX-702 has been completed in patients with moderate
to severe RA, demonstrating its good tolerance and
improvement in ACR20. Another p38 MAPK inhibitor,
ARRY-797 (Array Biopharma, Boulder, Colorado, USA)-
a selective and potent inhibitor of p38a- is currently in
preclinical development. This compound has proved to
be very effective in reducing the production of IL-6 and
TNF-a in rats challenged with lipopolysaccharide (LPS).
Furthermore, signs of inflammation and histopathological
changes of adjuvant-induced arthritis (AIA) were ame-
liorated [21]. Recently, ARRY-797 has advanced into
clinical trials to study its safety and efficacy in patients.
Another pathway closely related to p38 MAPK is
the MAPK kinase/extracellular signal-regulated kinase
(MEK/ERK) signalling cascade. This pathway is activated
in inflammatory conditions and has a role in increased
production of TNF-a and IL-1b. ARRY-162 (Array
Biopharma), another upcoming small molecule, selec-
tively inhibits MEK-1/2. Previously shown to be effica-
cious in AIA and collagen-induced arthritis (CIA), this
compound entered trials in healthy volunteers, demon-
strating good tolerability. Its inhibition of the MEK/ERK
pathway was assessed in ex-vivo measurements of the
production of TNF-a, IL1-b and IL-6 by whole blood
cells under stimulatory conditions. Clinical evaluation
of ARRY-162, in combination with MTX, in patients with
RA is ongoing [22].
Inhibition of transcription factors
Transcription factors bridge the interaction between
active receptors and transcriptional response in the
nucleus. Having this central function in cell activation,
they represent interesting targets for small molecules.
Activator protein-1 (AP-1) is a downstream target of p38
MAPK and c-Jun activated kinase (JNK) in response to
cytokines and cellular stress.
T-5224- a novel c-Fos/AP-1 inhibitor (Toyama Chemical,
Tokyo, Japan)- shows good promise as a new drug for
treatment of arthritis.T-5224was demonstrated toprevent
joint destruction, pannus formation and osteoclastogenesis
in CIA in rats. This effect was partially dependent on
the reduction of IL-1b and matrix metalloproteinase 3
(MMP-3) production [23]. A phase I clinical trial of this
interesting small molecule candidate has been initiated.
Small molecule inhibitor of IL-12/IL-23
IL-12 induces differentiation of naive T helper cells into
T helper cell type 1 (Th1) and is central to the patho-
genesis of Th1-mediated immunologic disorders. IL-23
shares the p40 protein subunit with IL-12 and plays a
critical role in the generation of effector T cells and IL-17
producing T cells. Apilimod mesylate (STA-5326;
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Synta Pharmaceuticals, Lexington, Massachusetts, USA)
is a novel oral small molecule inhibitor of IL-12/23. This
compound selectively inhibits production of IL-12/IL-23
through inhibition of nuclear translocation of c-Rel and
transcriptional inhibition of both IL-12 p35 and IL-12/
IL-23 p40 [24]. Preclinical studies [25] of STA-5326
demonstrated successful IL-12/IL-23 inhibition and sup-
pression of Th1-dependent immune response. In the
murine model of inflammatory bowel disease, STA-5326
inhibited the production of IFN-g and the development
of histopathologic changes in the colon, suggesting poten-
tial benefit of this compound for the treatment of
Th1-dependent autoimmune inflammatory diseases. So
far the drug was demonstrated to be efficacious in patients
with active, moderate to severe Crohn’s disease, as
assessed by reduction of theCrohn’s disease activity index
(CDAI) at day 28 of treatment [26]. Currently, the drug is
being evaluated in patients with RA in a phase II clinical
trial.
Small molecule interacting with cell surface
receptors
An interesting protein that emerges as a new ther-
apeutic target in RA is A3 adenosine receptor
(A3AR)- a Gi protein associated cell-surface receptor.
A3AR is highly expressed on mononuclear cells in
inflammatory conditions but has low expression in nor-
mal tissue [27]. Adenosine exerts anti-inflammatory
effects by activation of A3AR and downregulation of
NF-kB signalling, resulting in decrease of TNF-b
release and inhibition of proliferation of T cells [28].
Interestingly, release of adenosine partly accounts for
the immunomodulatory action of MTX. CF101 (Can-
Fite BioPharma, Lexington, Massachusetts, USA) is a
novel highly selectiveA3ARagonist. Recently published
data from the phase II clinical trial evaluating CF101 in
74 patients with RA demonstrated that therapy with
CF101 over 12 weeks is well tolerated and improves
signs and symptoms of arthritis, although statistical sig-
nificance was not reached. A double-blind randomized
placebo-controlled study [29], aimed at a definite evalu-
ation of the benefit of modulation of A3AR in RA, is
currently ongoing.
As synovial inflammation is dependent on the influx and
retention of inflammatory cells, therapies targeting che-
mokine receptors could represent a novel approach to
control chronic inflammation [30]. Some proofs of concept
studies are ongoing. Maraviroc (Pfizer), an oral selective
reversible antagonist of CCR5, of which RANTES
(regulated upon activation, normal T cell expressed and
secreted) is the major natural ligand, was recently
approved by the Food and Drug Administration (FDA)
for treatment of HIV infection and is currently tested in
patients with RA. A phase II clinical trial [31] is being
conducted to assess its safety and efficacy. At the same
time, another small molecule, MLN3897 (Millenium
Pharmaceuticals, Cambridge, Massachusetts, USA), an
inhibitor ofCCR1, a chemokine receptormostly expressed
on macrophages, failed to demonstrate improvement at
ACR20 in a phase II clinical trial in RA.
As costimulatory signals provided by CD80–CD28 inter-
action are necessary to fully activate T cells upon TCR
stimulation, CD80–CD28 interaction plays a critical role
in regulating T cell activation and is implicated in the
pathogenesis of autoimmunity. Recently, compounds
that selectively block binding of CD80 to CD28 have
been discovered and were shown to inhibit this inter-
action with high potency. RhuDex (Active Biotech,
Lund, Sweden)- an orally available CD80 antagonist-
is currently in phase II clinical evaluation in RA [32].
Due to their critical function in linking innate and
adaptive immunity and their proinflammatory proper-
ties, disease associated TLRs are appealing targets for
pharmacologic intervention [33]. 20-O-Methyl-modified
RNAs, acting as TLR7 antagonists, are able to signifi-
cantly reduce the production of IFN-g and IL-6 in
human peripheral blood mononuclear cells (PBMCs)
and in mice in vivo. Therefore, their potential utility in
the treatment of autoimmunediseases that involvesTLR7
stimulation like systemic lupus erythematosus (SLE) has
been suggested [34]. Another molecule that has been
recently demonstrated to provide therapeutical benefit
by engaging with TLR4 is Chaperonin 10 (Cpn 10)- a
heat shock protein. Cpn10 administered intravenously is
well tolerated andefficacious asprovedbyphase II double-
blind randomized trials in RA, psoriasis and multiple
sclerosis [35].
Efficacy and safety considerations
In order to provide an advance for rheumatic patients,
novel small molecules have to reach or exceed efficacy
and safety observed for biologics. The high rate of with-
drawals from the drug development process observed so
far for small molecule compounds indicates the existence
of numerous obstacles in the transition from the drug
discovery phase into the early development and finally
into clinical application. Inefficacy or high toxicity is the
most common reason for failures. Therefore, it is appar-
ent that major and constant efforts are needed to over-
come these problems. For instance, high-throughput
technologies such as gene arrays can be applied to
improve the drug development process [36]. Thereby,
measurements of changes in gene expression after treat-
ment in target cell populations can give information
about the intended target effects as well as about unde-
sired off-target properties of a drug. In addition, other
factors, like elaboration of clear guidelines regarding
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animal models assuring good translation of preclinical
data on clinical efficacy [37], good characterization of
patient cohorts as well as use of pharmacogenomics for
better prediction of patients who can benefit the most
from a given drug [38], might substantially augment
chances for successful development of novel oral anti-
inflammatory modalities. It also seems to be of crucial
importance to identify windows of opportunity during
disease progression, in which a given small molecule drug
is most beneficial.
Conclusion
The successful application of small molecule kinase
inhibitors in oncology provides a tremendous insight into
the signal transduction therapy and creates a foundation
for the extension of the application of small molecules to
rheumatology. As outlined in the overview, there are
currently a significant number of small molecule drugs
in the pipeline for treatment of inflammatory diseases,
with some promising molecules such as Jak-Stat and Syk
inhibitors on the horizon. At the same time, technological
advances, like systematic screening for new small mol-
ecule compounds and evaluation of potency and speci-
ficity of their interaction with a target structure, create
new possibilities for the development of even more novel
small molecules [39].
As the blockade of TNF-a leads to a remarkable
improvement in the ACR response, which cannot be
achieved by any tested small molecular drug so far, it is
tempting to speculate that oral inhibitors of TNF-a
would be a groundbreaking invention in the therapy
of rheumatic diseases. This undoubtedly remains an
enormous challenge for the drug industry. In disease
conditions, a number of signalling pathways contribute
to the activation of TNF-a, explaining why no single
kinase inhibitor can equal the efficacy of anti-TNF
agents. On the other hand, the fact that even with anti-
TNF-a biologics at the most 60% of patients achieve
an ACR70 response implicates that a considerable
part of disease-relevant mechanisms are not addressed
by currently available drugs. This indicates a big
potential of continued research focusing on cells that
have not been directly targeted so far, like, for example,
synovial fibroblasts [40]. Moreover, recent scientific
advances raise a possibility of molecular disturbances
on the level of microRNAome and epigenome, which
might require completely new therapeutic solutions
[41].
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